Heptabarbital: Difference between revisions

	WikiDoc Resources for Heptabarbital
Articles
Most recent articles on Heptabarbital Most cited articles on Heptabarbital Review articles on Heptabarbital Articles on Heptabarbital in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Heptabarbital Images of Heptabarbital Photos of Heptabarbital Podcasts & MP3s on Heptabarbital Videos on Heptabarbital
Evidence Based Medicine
Cochrane Collaboration on Heptabarbital Bandolier on Heptabarbital TRIP on Heptabarbital
Clinical Trials
Ongoing Trials on Heptabarbital at Clinical Trials.gov Trial results on Heptabarbital Clinical Trials on Heptabarbital at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Heptabarbital NICE Guidance on Heptabarbital NHS PRODIGY Guidance FDA on Heptabarbital CDC on Heptabarbital
Books
Books on Heptabarbital
News
Heptabarbital in the news Be alerted to news on Heptabarbital News trends on Heptabarbital
Commentary
Blogs on Heptabarbital
Definitions
Definitions of Heptabarbital
Patient Resources / Community
Patient resources on Heptabarbital Discussion groups on Heptabarbital Patient Handouts on Heptabarbital Directions to Hospitals Treating Heptabarbital Risk calculators and risk factors for Heptabarbital
Healthcare Provider Resources
Symptoms of Heptabarbital Causes & Risk Factors for Heptabarbital Diagnostic studies for Heptabarbital Treatment of Heptabarbital
Continuing Medical Education (CME)
CME Programs on Heptabarbital
International
Heptabarbital en Espanol Heptabarbital en Francais
Business
Heptabarbital in the Marketplace Patents on Heptabarbital
Experimental / Informatics
List of terms related to Heptabarbital

Heptabarbital
Clinical data
Synonyms	G-475
Pregnancy; category	?;
Routes of; administration	Oral
ATC code	N05CA11 (WHO) ;
Legal status
Legal status	?;
Pharmacokinetic data
Bioavailability	83%
Metabolism	Hepatic
Elimination half-life	6.1-11.2 hours
Excretion	Renal
Identifiers
	IUPAC name 5-cyclohept-1-en-1-yl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione;
CAS Number	509-86-4;
PubChem CID	10518;
DrugBank	DB01354 ;
ChemSpider	10081 ;
UNII	V10R70ML23;
KEGG	C17725 ;
ChEMBL	ChEMBL468837 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C13H18N2O3
Molar mass	250.294 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C1NC(=O)NC(=O)C1(/C2=C/CCCCC2)CC;
	InChI InChI=1S/C13H18N2O3/c1-2-13(9-7-5-3-4-6-8-9)10(16)14-12(18)15-11(13)17/h7H,2-6,8H2,1H3,(H2,14,15,16,17,18) ; Key:PAZQYDJGLKSCSI-UHFFFAOYSA-N ;
(verify)

VisualWikitext

Latest revision as of 13:43, 15 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Heptabarb (INN; Eudan, Medapan, Medomin, Noctyn), also known as heptabarbitone (BAN) or heptabarbital, is a sedative and hypnotic drug of the barbiturate family.^[2]^[3] It was previously used in Europe for the treatment of insomnia from the 1950s onwards, but has since been discontinued.^[2]^[3]

References

↑ ^1.0 ^1.1 ^1.2 ^1.3 Breimer DD, de Boer AG (December 1975). "Pharmacokinetics and relative bioavailability of heptabarbital and heptabarbital sodium after oral administration to man". European Journal of Clinical Pharmacology. 9 (2–3): 169–78. doi:10.1007/bf00614014. PMID 9299.
↑ ^2.0 ^2.1 C. R Ganellin; D. J Triggle; F.. Macdonald (1997). Dictionary of pharmacological agents. CRC Press. p. 1003. ISBN 978-0-412-46630-4. Retrieved 26 November 2011.
↑ ^3.0 ^3.1 Index nominum 2000: international drug directory. Taylor & Francis US. 2000. p. 513. ISBN 978-3-88763-075-1. Retrieved 26 November 2011.

Template:GABAAR PAMs

Template:Sedative-stub

[pmid9299-1] 1.0 ^1.1 ^1.2 ^1.3 Breimer DD, de Boer AG (December 1975). "Pharmacokinetics and relative bioavailability of heptabarbital and heptabarbital sodium after oral administration to man". European Journal of Clinical Pharmacology. 9 (2–3): 169–78. doi:10.1007/bf00614014. PMID 9299.

[GanellinTriggle1997-2] 2.0 ^2.1 C. R Ganellin; D. J Triggle; F.. Macdonald (1997). Dictionary of pharmacological agents. CRC Press. p. 1003. ISBN 978-0-412-46630-4. Retrieved 26 November 2011.

[Index_nominum_2000:_international_drug_directory-3] 3.0 ^3.1 Index nominum 2000: international drug directory. Taylor & Francis US. 2000. p. 513. ISBN 978-3-88763-075-1. Retrieved 26 November 2011.

[1]

[2]

[3]

@@ Line 1: / Line 1: @@
-{{Drugbox|
+{{Drugbox
-|IUPAC_name = ''5-(1-cycloheptenyl)-5-ethyl-1,3-diazinane-2,4,6-trione''
+| verifiedrevid = 443853293
-| image = heptabarbital.svg
+| IUPAC_name = 5-cyclohept-1-en-1-yl-5-ethylpyrimidine-2,4,6(1''H'',3''H'',5''H'')-trione
-| width=180
+| image = Heptabarb Wiki str.png
-| CAS_number=509-86-4
-| ATC_prefix=N05
+| width = 180
-| ATC_suffix=CA11
-| ATC_supplemental=
+<!--Clinical data-->
-| PubChem=10518
+| tradename =
-| DrugBank=
-| C=13 | H=18 | N=2 | O=3
-| molecular_weight = 250.294
-| bioavailability= ?
-| metabolism = [[Hepatic]]
-| elimination_half-life= ?
-| excretion = [[Renal]]
 | pregnancy_category = ?
 | legal_status = ?
-| routes_of_administration= Oral
+| routes_of_administration = Oral<ref name="pmid9299">{{cite journal | author = Breimer DD, de Boer AG | title = Pharmacokinetics and relative bioavailability of heptabarbital and heptabarbital sodium after oral administration to man | journal = European Journal of Clinical Pharmacology | volume = 9 | issue = 2-3 | pages = 169–78 |date=December 1975 | pmid = 9299 | doi = 10.1007/bf00614014| url = }}</ref>
+<!--Pharmacokinetic data-->
+| bioavailability = 83%<ref name="pmid9299" />
+| metabolism = [[Hepatic]]
+| elimination_half-life = 6.1-11.2 hours<ref name="pmid9299" />
+| excretion = [[Renal]]<ref name="pmid9299" />
+<!--Identifiers-->
+| CASNo_Ref = {{cascite|correct|CAS}}
+| CAS_number = 509-86-4
+| ATC_prefix = N05
+| ATC_suffix = CA11
+| PubChem = 10518
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
+| DrugBank = DB01354
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
+| ChemSpiderID = 10081
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = V10R70ML23
+| KEGG_Ref = {{keggcite|correct|kegg}}
+| KEGG = C17725
+| ChEMBL_Ref = {{ebicite|correct|EBI}}
+| ChEMBL = 468837
+| synonyms = G-475
+<!--Chemical data-->
+| C = 13 | H = 18 | N = 2 | O = 3
+| molecular_weight = 250.294 g/mol
+| smiles = O=C1NC(=O)NC(=O)C1(/C2=C/CCCCC2)CC
+| InChI = 1/C13H18N2O3/c1-2-13(9-7-5-3-4-6-8-9)10(16)14-12(18)15-11(13)17/h7H,2-6,8H2,1H3,(H2,14,15,16,17,18)
+| InChIKey = PAZQYDJGLKSCSI-UHFFFAOYAO
+| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChI = 1S/C13H18N2O3/c1-2-13(9-7-5-3-4-6-8-9)10(16)14-12(18)15-11(13)17/h7H,2-6,8H2,1H3,(H2,14,15,16,17,18)
+| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChIKey = PAZQYDJGLKSCSI-UHFFFAOYSA-N
 }}
-'''Heptabarbital''' is a drug which is a [[barbiturate]] derivative.
+__NOTOC__
+{{SI}}
+{{CMG}}
+== Overview ==
+'''Heptabarb''' ([[International Nonproprietary Name|INN]]; '''Eudan''', '''Medapan''', '''Medomin''', '''Noctyn'''), also known as '''heptabarbitone''' ([[British Approved Name|BAN]]) or '''heptabarbital''', is a [[sedative]] and [[hypnotic]] [[drug]] of the [[barbiturate]] family.<ref name="GanellinTriggle1997">{{cite book | author1 = C. R Ganellin | author2 = D. J Triggle | author3 = F.. Macdonald | title = Dictionary of pharmacological agents | url = http://books.google.com/books?id=A0THacd46ZsC&pg=PA1003 | accessdate = 26 November 2011 | year = 1997 | publisher = CRC Press | isbn = 978-0-412-46630-4 | page = 1003}}</ref><ref name="Index nominum 2000: international drug directory">{{cite book | title = Index nominum 2000: international drug directory | url = http://books.google.com/books?id=5GpcTQD_L2oC&pg=PA513 | accessdate = 26 November 2011 | year = 2000 | publisher = Taylor & Francis US | isbn = 978-3-88763-075-1 | page = 513}}</ref> It was previously used in [[Europe]] for the treatment of [[insomnia]] from the 1950s onwards, but has since been discontinued.<ref name="GanellinTriggle1997" /><ref name="Index nominum 2000: international drug directory" />
+== See also ==
+* [[Barbiturate]]
+== References ==
+{{Reflist|2}}
-{{barbiturates}}
 {{Hypnotics and sedatives}}
+{{GABAAR PAMs}}
+[[Category:drug]]
 [[Category:Barbiturates]]
+[[Category:Hypnotics]]
+[[Category:Ketones]]
+[[Category:Pyrimidines]]
 [[Category:Sedatives]]
+[[Category:Cycloalkenes]]
+[[Category:GABAA receptor positive allosteric modulators]]
-{{pharma-stub}}
+{{sedative-stub}}
-[[de:Heptabarbital]]
-[[sv:Heptabarbital]]
-{{WikiDoc Sources}}

Clinical data

Synonyms	G-475
Pregnancy category	?
Routes of administration	Oral^[1]
ATC code	N05CA11 (WHO)
Legal status
Legal status	?
Pharmacokinetic data
Bioavailability	83%^[1]
Metabolism	Hepatic
Elimination half-life	6.1-11.2 hours^[1]
Excretion	Renal^[1]
Identifiers
IUPAC name 5-cyclohept-1-en-1-yl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione
CAS Number	509-86-4
PubChem CID	10518
DrugBank	DB01354^Y
ChemSpider	10081^Y
UNII	V10R70ML23
KEGG	C17725^Y
ChEMBL	ChEMBL468837^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₃H₁₈N₂O₃
Molar mass	250.294 g/mol
3D model (JSmol)	Interactive image
SMILES O=C1NC(=O)NC(=O)C1(/C2=C/CCCCC2)CC
InChI InChI=1S/C13H18N2O3/c1-2-13(9-7-5-3-4-6-8-9)10(16)14-12(18)15-11(13)17/h7H,2-6,8H2,1H3,(H2,14,15,16,17,18)^Y Key:PAZQYDJGLKSCSI-UHFFFAOYSA-N^Y
(verify)

Heptabarbital: Difference between revisions

Latest revision as of 13:43, 15 April 2015

Overview

See also

References

Navigation menu

Search